Main content

    Liver Cancer
    (Hepatoma / Hepatocellular Carcinoma / HCC)

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    First Line Treatment  |  Second Line Treatment

    Active Trials

    First Line Treatment

    Title: A Phase 2, Open Label Study of Dalantercept Plus Sorafenib in Patients With Advanced Hepatocellular Carcinoma
    Description: This study is to evaluate the safety and tolerability of dalantercept plus sorafenib in patients with advanced hepatocellular carcinoma (HCC) to determine the recommended dose level of dalantercept in combination with sorafenib
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older, with histologically confirmed, locally advanced or metastatic HCC with at least one target lesion that has not been treated with local therapy
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Acceleron HCC

    Back to top

    Active Trials

    Second Line Treatment

    Title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Following First-Line Therapy With Sorafenib
    Description: The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older, with a diagnosis of HCC based on histopathologic findings, or a diagnosis of cirrhosis and a tumor with classical HCC imaging characteristics
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Lilly JVDE

    Title: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
    Description: Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older, who have a Histological or cytological diagnosis of HCC
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Exelixis:XL184-309

    • updated August 2015

    Back to top